Ocugen Showcases Gene Therapy Progress in July

For the inherited retinal disease (IRD) community, industry updates and scientific presentations offer important visibility into emerging therapeutic pipelines. According to The Manila Times, Ocugen, Inc. announced plans to present its modifier gene therapy platform at several investor and industry events throughout July 2026.

Key Conference Presentations and Events

The company's schedule features multiple prominent panels and discussions detailing its approach to treating blindness diseases:

  • Piper Sandler Virtual Ophthalmology Day: Held on Friday, July 10, 2026, featuring a fireside chat with Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen.
  • OIS (Ophthalmology Innovation Source) Retina Innovation Summit: Taking place on Tuesday, July 14, 2026, in Montreal, company leadership participated in a panel titled “Regenerative Approaches in Retinal Disease: From Genetic Repair to Functional Restoration”.
  • ASRS (American Society of Retina Specialists) Annual Meeting: Scheduled for Friday, July 17, 2026, in Montreal, presentations included the OCU410 Phase 2 ArMaDa 1-year results as well as Phase 1/2 quantitative FAF/SD-OCT analysis and safety outcomes.

What This Means for Patients and Families

Ocugen reports that its modifier gene therapy platform takes a gene-agnostic approach designed to address complex diseases potentially caused by imbalances in multiple gene networks, contrasting with traditional single-gene replacement strategies. The company currently maintains development programs targeting conditions affecting millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy (an advanced form of dry age-related macular degeneration). Publicly shared clinical data and expert discussions help patients and families stay informed on the evolving landscape of genetic and regenerative ophthalmology.

Looking Ahead

Webcasts and replays for key presentations are made available through the investor relations section of Ocugen's website, providing ongoing access for community members interested in following clinical development milestones.